Timelines are made to be broken. Remember the anticipated closing of the Zenith Capital Corp and Zenith Epigenetics Ltd was Feb 2016! As for the trial timeline though, I don't think a shift of 1-3 months is that big of a deal, especially now that we know the trial is recruiting, dosing and is funded.

I agree, something seems to have caused a delay in things from the Jan 7th update. As for the trial(s), I beleive the original plan was to start with some dose finding with ZEN003694 alone first, prior to proceeding to the onset of the other trial in combination with Enzalutamide. ClinicalTrials.gov only lists the first trial as recruiting right now.

I also sent questions to Zenith regarding 1) the autoimmune program, and 2) What differentiated RVX from Zenith for compounds, IP, and disease indications. Hopefully, these questions and many more will be answered at the webcast.

BearDownAZ